Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could spot hidden cancers in High-Risk patients

NCT ID NCT04261972

Diagnosis Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is developing a blood test to find early-stage tumors in people with hereditary cancer syndromes (high genetic risk for cancer). Researchers will collect blood samples and medical data from about 1,400 participants across Canada. They will also interview patients and doctors to see if this test is useful and practical for routine cancer screening.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,416 people

The number who actually took part.

Started

Jul 2018

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The population to be studied includes: 1. Any individual that underwent clinical genetic testing for hereditary breast and ovarian cancer syndrome or Lynch Syndrome and was found to carry a detectable variant that is likely pathogenic or pathogenic. 2. Any individual with a suspected cancer predisposition that has not yet received genetic testing. 3. Any individual who received negative genetic test results but has a strong personal or family history of cancer.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Individual with any known or suspected hereditary cancer predisposition (i.e. individuals with an identified pathogenic or likely pathogenic variant in a cancer predisposition gene and/or a family history of cancer without an identified gene mutation) at any stage in their cancer journey (ie: cancer survivor, unaffected with cancer, current cancer patient). 2. Individual must be greater than 18 years of age 3. Individual must speak English or French to participate in the qualitative interview and/or survey Exclusion Criteria: 1\. Individuals that do not meet the outlined inclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary cancer syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Colorectal Neoplasms, Hereditary Nonpolyposis hereditary breast ovarian cancer syndrome hereditary neoplastic syndrome neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary cancer syndrome

Contacts and locations

Locations

  • BC Cancer Agency

    Vancouver, British Columbia, V5Z 4E6, Canada

  • Eastern Health

    St. John's, Newfoundland and Labrador, A1B 3V6, Canada

  • IWK Health Centre

    Halifax, Nova Scotia, B3K 6R8, Canada

  • Jewish General Hospital

    Montreal, Quebec, H3T 1E2, Canada

  • Sinai Health System

    Toronto, Ontario, M5G 1X5, Canada

  • University Health Network

    Toronto, Ontario, M5G 2M9, Canada

  • Women's College Hospital

    Toronto, Ontario, M5S 1B2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.